The Obesity Drug Race Is Being Defined by Pricing -- Market Talk

Dow Jones03:15

1515 ET - For obesity-drug makers, success will be defined by price rather than product differentiation, HSBC analysts say. Pricing competition is set to heat up between Eli Lilly and Novo Nordisk, the analysts say. Lilly's current guidance -- which is more optimistic than Novo Nordisk's -- implies it will get a surge in GLP-1 demand when it cuts prices. However, the analysts aren't as confident that customers will rush to buy the products, even at a lower price, if there are economic disruptions like a sluggish job market. Meanwhile, Novo Nordisk's deal to sell products with Hims & Hers Health could help the company offer lower prices and gain demand, the analysts say. (katherine.hamilton@wsj.com)

(END) Dow Jones Newswires

March 17, 2026 15:15 ET (19:15 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment